Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination.
Some combinations of antihypertensive agents were shown to reduce proteinuria in patients with renal failure. However, preventive effects of such combinations on renal structure and function are presently unknown when treatment is administered before the onset of renal abnormalities. We thus investigated the long-term effects of an angiotensin-converting enzyme (ACE) inhibitor (perindopril)/diuretic (indapamide) combination (per/ind) in the Zucker rat, a classical model of chronic renal failure associated with obesity, hyperlipidemia, and insulin resistance. Two-month-old lean and obese Zucker rats, presenting normal renal structure and function at this young age, received per/ind (0.76 + 0.24 mg/kg of body weight/day) or the vehicle of this combination by daily gavage. After 8.5 consecutive months of treatment, those 10.5-month-old rats were used for determination of renal structural and functional parameters which were examined using standard renal clearance experiments and kidney tissue analysis. Per/ind prevented focal and segmental glomerular hyalinosis and tubulo-interstitial damage in obese rats. Treatment was also associated with a significant reduction in several staining markers of glomerular and interstitial fibrosis. The hypertrophy of superficial glomeruli and the mesangial expansion of deep glomeruli observed in control rats were reduced in per/ind-treated obese rats. The severe proteinuria observed in 10.5-month-old control obese rats was prevented by per/ind, while glomerular filtration and renal hemodynamic parameters reached similar values to those obtained in lean animals. These results show that long-term treatment with this ACE inhibitor/diuretic combination protects renal structure and function in the obese Zucker rat, emphasizing the potential efficiency of such therapy in renal failure prevention.
Renaud
Isabelle M
IM
INSERM U 430, Broussais Hospital and Claude Bernard Association, Paris, France.
Chainey
Angele
A
Belair
Marie-France
MF
Mandet
Chantal
C
Michel
Odile
O
Myara
Isaac
I
Chevalier
Jacques
J
Plante
Gerard E
GE
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D004232:Diuretics / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004338:Drug Combinations; D005355:Fibrosis / Q000517:prevention & control; D007190:Indapamide / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007677:Kidney Function Tests; D008297:Male; D008657:Metabolic Clearance Rate; D009765:Obesity / Q000150:complications; D020913:Perindopril / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011507:Proteinuria / Q000209:etiology / Q000517:prevention & control*; D051381:Rats; D011924:Rats, Zucker; D051437:Renal Insufficiency / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*
D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D004338:Drug Combinations; D007190:Indapamide; D020913:Perindopril